Clinical Peptide Protocols: A Complete Prescriber's Guide

NP prescribers are fielding patient questions about clinical peptide protocols and peptide therapy every week, yet most available educational content falls into one of two unhelpful categories: oversimplified biohacker content with no clinical rigor, or dense pharmacology literature with no practical framework for everyday practice. Neither gets you to the point where you can write a defensible prescription with confidence.

The honest regulatory reality needs to be stated upfront. The peptides most commonly used in functional medicine settings, including BPC-157, sermorelin, ipamorelin, and thymosin beta-4, are not FDA-approved for human use. No phase III trial has established an official dosing standard for any of them. That is not a reason to dismiss peptide therapy. It is the reason every prescriber needs documented, systematic clinical peptide protocols rather than relying on what a patient read in a wellness forum.

A sound approach to peptide prescribing covers five components: patient selection, dosing, reconstitution, monitoring, and documentation. Platforms like IMED University (Intellectual Medicine University) have structured this exact framework into accredited certification programs with downloadable protocol templates that plug directly into clinical workflows. This guide is modeled on that same structure.

Understanding the Evidence Landscape Before You Write Your First Peptide Rx

The actual regulatory status of the most-used peptides

BPC-157, sermorelin, ipamorelin, and thymosin beta-4 are not FDA-approved, and current dosing used in practice is extrapolated from animal studies or small pilot data. The only peptides with robust clinical trial support are metabolic agents: tirzepatide (FDA-approved dual GIP/GLP-1 agonist), semaglutide, and tesamorelin. Frame this as essential clinical context. Every prescription you write for a non-approved peptide needs a documented clinical rationale, not because you are doing something reckless, but because prescribing without documentation is where providers run into trouble.

Where the clinical evidence is actually moving

BPC-157 has Phase II trials underway in IBD (NCT04919239, 240 participants), tendon healing (120 participants), and chronic wounds (180 participants), though peer-reviewed results have not yet been published for most of these programs. GHK-Cu shows early promise for dermal regeneration in preclinical models. TB-500 remains preclinical and is banned in competitive sports. Metabolic peptide administration protocols have the strongest current backing and the clearest prescribing pathway. Understanding where each peptide sits on the evidence spectrum shapes how you document your clinical rationale.

Clinical Peptide Protocols, Patient Selection

Clinical indications and contraindication screening

Primary indications for therapeutic peptide protocols include tissue regeneration and recovery, growth hormone secretion support, metabolic optimization, anti-inflammatory support, and wound healing. Contraindication screening deserves careful attention across four categories:

• Active malignancy is a hard stop for GH secretagogues because IGF-1 stimulation can accelerate tumor growth.

• Uncontrolled diabetes warrants caution since GH peptides transiently decrease insulin sensitivity.

• Pregnancy and breastfeeding are absolute contraindications.

• Active autoimmune flares complicate inflammatory-pathway peptides and require careful risk-benefit documentation.

Patient selection documentation is not a formality. It is the first line of legal defensibility when a board audit or patient complaint arises.

Intake evaluation components

The intake evaluation needs to cover a symptom timeline, prior treatment history, current medication review for interaction risks, review of any prior labs, and clear documentation of why conventional FDA-approved alternatives were considered and why the patient and provider agreed peptide therapy was appropriate. This "medical necessity" documentation is a specific regulatory requirement for compounded peptide prescriptions, not just a clinical best practice. Providers who skip this step are not just cutting corners clinically; they are creating a gap in the compliance record that can surface months later.

Clinical Peptide Protocols: Dosing and Reconstitution

Extrapolated dosing ranges by peptide class (with honest caveats)

These ranges are drawn from animal-extrapolated and pilot data. They are clinical starting points, not validated guidelines, and should be treated accordingly in both your prescribing and your chart documentation. Some entries below follow validated titration schedules; others reflect extrapolated estimates where no formal titration protocol exists.

• BPC-157: 200, 500 mcg/day subcutaneously; a common split is 250 mcg twice daily; typical cycle is 4, 8 weeks on, 4, 8 weeks off. Weight-based peptide dosing guidelines estimate approximately 2.5, 3.75 mcg/kg twice daily for a 70 kg adult.

• Sermorelin/Ipamorelin: 100, 300 mcg subcutaneously, 1, 3 times daily, typically administered at bedtime to align with the natural GH pulse. Both remain on the FDA Category 1 bulk drug substances list for 503A compounding.

• Thymosin Beta-4: Evidence remains preclinical. No validated human dosing range exists, and this should be communicated directly to patients before any trial use.

• Metabolic peptides (tirzepatide, semaglutide): Follow FDA-approved titration schedules with no extrapolation required.

Step-by-step reconstitution and storage protocol

Proper peptide reconstitution and storage protect peptide integrity and patient safety. Allow vials to reach room temperature 10- 20 minutes before use, then sterilize stoppers with 70% isopropyl alcohol and let them air dry for 30 seconds. Use bacteriostatic water (0.9% benzyl alcohol) as the standard solvent; this provides a 28, 30 day refrigerated shelf life by inhibiting bacterial growth. Inject the solvent slowly down the vial wall at an angle rather than directly onto the powder, which prevents foaming that can denature peptide molecules at the air-water interface. Swirl gently for 1, 5 minutes and never shake the vial.

Store reconstituted peptides at 2- 8°C, protected from light. Label every vial immediately after mixing with the peptide name, concentration in mg/mL, reconstitution date, and expiration date. If you are using sterile water instead of bacteriostatic water, the shelf life drops to 48 hours, and single-use aliquots with freezing are required. That is a practical reason most clinical settings default to bacteriostatic water for multi-dose vials.

Clinical Peptide Protocols, Monitoring and Documentation

Baseline labs every peptide patient needs before dose one

A complete baseline panel confirms indication, establishes a safety reference, and creates the evidentiary record for ongoing prescribing decisions. The universal panel includes CBC with differential, CMP (ALT, AST, creatinine, eGFR), lipid panel, hs-CRP, and HbA1c. For GH secretagogues like sermorelin and ipamorelin, IGF-1 measured against age-adjusted reference ranges is the critical safety and efficacy marker; the therapeutic target is typically the middle-to-upper third of the age-specific range, which for a 40- to 59-year-old adult runs 60.8, 297.7 ng/mL. Metabolic peptide protocols require fasting glucose, fasting insulin, and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance).

Hormone-affecting peptides require a full sex hormone panel, TSH/T3/T4, and cortisol. Men over 40 need a PSA at baseline. Document the clinical purpose of each marker directly in the chart so that the rationale for every follow-up test is traceable to the initial prescribing decision.

The three-phase follow-up schedule

During the initiation phase (weeks 1, 4), conduct weekly symptom check-ins and vitals, with focused safety labs at week 4 covering glucose, insulin, and liver enzymes. The stabilization phase (months 2, 3) requires a full reassessment panel at 8 and 12 weeks, including IGF-1, HbA1c, CMP, lipids, and fasting insulin, followed by a clinical evaluation for dose adjustment. Maintenance means repeating key markers quarterly and running a comprehensive full panel, including thyroid, CBC, and full hormone profile, every 6 and 12 months.

Know your adverse event triggers. An ALT elevation greater than three times baseline requires immediate dose cessation. Rising fasting insulin on a GH secretagogue signals dose reduction. Alongside IGF-1 monitoring, screen for acromegaloid features like joint swelling and facial changes at every clinical evaluation. These are not theoretical concerns; they are the specific outcomes that get providers in front of licensing boards when missed.

What your informed consent document must cover

Prescribing a compounded or off-label peptide in the United States requires written, signed informed consent stored in the medical record. The consent must explicitly state the peptide is not FDA-approved for human use and describe the evidence base as preclinical or limited. It must cover known and theoretical risks, including acknowledgment that some risks remain uncharacterized, and document that FDA-approved alternatives were discussed. The document should also include the monitoring plan, insurance coverage status (typically none for peptide protocols), and re-consent language for long-term prescribing as the regulatory landscape evolves.

Record-keeping and compounding pharmacy verification

Every prescription requires documented clinical rationale, a medical necessity statement explaining why a commercially available FDA-approved alternative was not appropriate, and the diagnosis and contraindication review. Source verification is mandatory: record the compounding pharmacy name, its 503A or 503B status, its FDA registration, and a Certificate of Analysis (COA) confirming identity, purity, and sterility testing for that specific lot. For telehealth encounters, add the modality used, the patient's physical location at the time of consult, encounter start and stop times, and a separate telehealth consent.

FDA enforcement of peptide compounding is tightening. The Category 1 bulk drug substances list governs what can legally be compounded, and that list has shifted significantly since early 2025. Providers must verify at the time of prescribing that their selected peptide is not on the "Do Not Compound" list. This is not a one-time check; it is an ongoing compliance step because the list changes.

Where to Get Structured Peptide Therapy Training and Ready-Made Clinical Protocols

Why certification matters before you prescribe

NP boards and malpractice carriers are increasingly scrutinizing peptide prescribing, and that scrutiny is not slowing down. Documented, structured training in clinical peptide prescribing protocols through an accredited CME/CEU program is not just professional development. It is a defensibility asset. Certification demonstrates that your prescribing practices are grounded in current clinical education, which carries direct weight during a board audit or patient complaint review. Providers who learned peptide dosing from a vendor webinar or a patient-facing wellness site are in a very different position than those who completed formal clinical education with documented competency verification.

IMED University's peptide therapy certification and DocuHub protocol library

IMED University (Intellectual Medicine University) offers a peptide therapy certification course developed by actively practicing functional medicine clinicians, covering clinical indications, evidence-based dosing frameworks, monitoring parameters, and compounding compliance requirements. The course is built for immediate implementation, not abstract education. Beyond the CEU credits, IMED's DocuHub library gives course graduates access to 300+ downloadable clinical protocols, informed consent templates, monitoring schedules, and EMR-ready documentation that can be imported into existing electronic health records the same day. For providers building or expanding a cash-pay functional medicine practice, that combination addresses clinical competency, documentation infrastructure, and medication sourcing through a single platform.

Building a Framework That Holds Up as Regulations Evolve

The five-component framework covers the full prescribing cycle: patient selection grounded in documented medical necessity, dosing ranges drawn from the best available extrapolated data with honest caveats, precise reconstitution and storage practices, a structured three-phase monitoring schedule, and airtight informed consent and compliance documentation. No component is optional. A gap in any one of them is where clinical and regulatory exposure lives.

The evidence base for peptide therapy is evolving. Phase II results for BPC-157 are pending peer review. The FDA Category 1 compounding list is being revised. State telehealth prescribing rules for compounded medications are tightening in several major markets, including California, New York, and Massachusetts. Providers who build systematic, auditable clinical peptide protocols now will be better positioned as that regulatory environment continues to shift, rather than scrambling to catch up after the fact.

If you are adding or expanding peptide protocols in your practice, the fastest and most defensible path forward is structured certification training paired with plug-and-play documentation. IMED University covers both clinical competency and practice-ready clinical peptide protocols in a single platform, so you are not assembling a compliance framework from five different sources while also trying to see patients.

References

1. Ipamorelin, the first selective growth hormone secretagogue. Smith RG, et al. Endocrine Reviews. 1997.
2. Growth hormone secretagogues and peptide therapy in aging and body composition. Bartke A, et al. Frontiers in Endocrinology. 2021.
3. BPC-157 and its role in healing, angiogenesis, and tissue repair. Sikiric P, et al. Current Pharmaceutical Design. 2018.
4. AOD-9604 and fat metabolism research in obesity management. Ng FM, et al. Obesity Research. 2000.
5. Peptide therapeutics: current status and future directions. Fosgerau K, Hoffmann T. Drug Discovery Today. 2015.